SUBSCRIBE
SUBSCRIBE
News   Drug Development

Phynova Obtains FDA Approval Of Its IND To Enter Into A Clinical Trial Of PYN17 For The Treatment Of Chronic Hepatitis C

January 8, 2007 | 
1 min read
Phynova Group PLC (AIM: PYN), a developer of pharmaceuticals derived from Chinese botanical drugs targeting viral and metabolic diseases and cancer, is pleased to announce the introduction of its first drug candidate into clinical trials in the US.
Clinical research Phase I Europe
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Profile view, and Mental Illness
Depression
Alto Digs Into Exploratory Outcomes as Depression Drug Misses Phase II Endpoint
June 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Artwork magazine collage picture of serious confident lady looking big enlargement glass isolated drawing background.
Immunology and inflammation
Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced
June 25, 2025
 · 
3 min read
 · 
Tristan Manalac
Illustration showing scientist climbing up DNA spiral staircase
Gene therapy
Sangamo’s ‘Positive’ Phase I/II Data for Fabry Gene Therapy Opens Path to FDA
June 24, 2025
 · 
3 min read
 · 
Tristan Manalac
People And Robots Handshake Modern Human And Artificial Intelligence Futuristic Mechanism Technology Vector Illustration
Artificial intelligence
In latest AI Play, Sanofi Bets $630M+ for Formation Bio’s JAK/SYK Blocker
June 24, 2025
 · 
2 min read
 · 
Tristan Manalac